Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (649) clinical trials

The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...

Phase

Multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate the safety and tolerability, efficacy, and PK of 60 mg and 90 mg AD-35 administered QD during 6 months of double-blind treatment followed by a second 6 months of open-label treatment to subjects with mild to moderate AD.  

Phase

The Trailblazer study is investigating the safety, tolerability, and efficacy of an investigational drug on symptoms of cognitive and functional decline in individuals with early Alzheimer's disease. The study drug is an infusion that will be administered once per week for 75 weeks. The study will last approximately two and ...

Phase

The TauRX study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild  Alzheimer's disease, compared to a placebo. The study drug is a tablet which is taken by mouth twice per day. The study will last approximately 8 months.  

Phase

A research study is evaluating an investigational medication for symptoms of early onset Alzheimer’s Disease.  

Phase N/A

RenewTM NCP-5, an ECP device, is a non-invasive treatment that improves coronary and peripheral vascular health and may improve cerebral vascular health. It enhances circulation and stimulates endothelial production of trophic factors such as nitric oxide, resulting in peripheral vasodilation, reduction in vascular inflammation and improved vascular compliance. These and ...

Phase

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) ...

Phase

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

Phase

To take part, your loved one must:  be at least 55 years of age,  be diagnosed with probable Alzheimer’s disease,  be showing behaviors of agitation associated with Alzheimer’s,  have a friend or loved one that can take part in the study with them.

Phase

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

Phase